PubMed · 11661339
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
Cheryl M Fields. 1976-07-06. High-risk genetics study gets NIH guidelines.. https://pubmed.ncbi.nlm.nih.gov/11661339/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
The Ustilago maydis mig1 gene is extensively up-regulated during growth within its host plant. A genetic approach was set up to identify mutants expressing mig1 during axenic growth. Five independent mutants were identified that not only displayed increased transcript levels of mig1 but also of egl1, an endoglucanase expressed in dikaryotic filaments. egl1 has recently been shown to be repressed by Hda1, a putative histone deacetylase [Reichmann et al., submitted]. The identified UV mutants shared other phenotypes with hda1 deletion mutants like enhanced pigmentation and the inability to produce teliospores in maize tumours. Complementation and sequence analysis demonstrated that all five UV mutants contained point mutations in the hda1 gene. Despite a common repression mechanism, expression levels of mig1 and egl1 were significantly different during axenic and biotrophic growth, providing evidence for additional regulatory inputs from the respective growth stage. Furthermore, while egl1 is subject to repression by the U. maydis regulator Rum1, this was not the case for mig1. U. maydis strains deleted in either hda1 or rum1 were not affected in mig1 expression in the tumour stage. Transcript levels conferred by mig1 promoters deleted in negatively cis-acting sequences exceeded those in hda1 mutants, suggesting additional negative factors governing mig1 expression.
In an attempt to exploit the remarkable tissue-tropism of the human parvovirus B19 to target human hematopoietic cells of the erythroid lineage, recombinant human adeno-associated virus 2 genomes were encapsidated in parvovirus B19 capsids. Although efficient transduction of primary human hematopoietic cells in the erythroid lineage occurred, a low-level of transgene expression in non-erythroid cells was also detected. These studies suggest that cell surface expression of P antigen, the primary receptor for parvovirus B19, is necessary but not sufficient for parvovirus B19 vector-mediated transduction of human hematopoietic cells. These studies also suggest the existence of a putative cell surface co-receptor, which is required for successful infection of human hematopoietic cells by parvovirus B19.
Herpes simplex virus (HSV) may be engineered to produce flexible and efficient gene delivery vectors. Recent advances in vector design and production have built on increasing understanding of the basic biology of HSV to minimise vector toxicity and exploit viral features that give rise to lifelong latent infection in the nervous system. In addition, the emerging picture of viral cell entry has allowed early steps to be taken towards targeting viral entry to predetermined cellular subsets. Recent work has established sound principles for the straightforward production of large-scale pure preparations of vector stocks for clinical applications.